PROactive study [1]

Lancet

Volumn 367, Issue 9504, 2006, Pages 23-

  Goldstein, Mark R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

BLADDER CANCER; BLADDER CARCINOGENESIS; CARCINOGENICITY; DOSE RESPONSE; DRUG MECHANISM; HEMATURIA; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; RODENT; ANIMAL; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RAT;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RATS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 29844442291     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)67910-5     Document Type: Letter

References (3)

1. JA Dormandy, B Charbonnel, DJA Eckland on behalf of the PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
2. HP Koeffler Peroxisome proliferator-activated receptor gamma and cancers Clin Cancer Res 9 2003 1 9
3. Takeda Pharmaceuticals America. Actos package insert 2004 Takeda Pharmaceuticals America Lincolnshire, IL